A Brazilian research team has published a detailed plan for a five-arm crossover trial to measure how oral cannabis and THC oils affect cardiovascular hemodynamics and respiratory muscle activity in healthy adults. The protocol is rigorous in design, but it contains no results whatsoever and cannot yet support any conclusion about cannabis safety or efficacy on the heart or breathing muscles.

Oral cannabis oils are prescribed with increasing frequency for pain, spasticity, and other conditions, yet clinicians have almost no standardized data on how these formulations acutely affect cardiovascular hemodynamics or respiratory muscle function. Dosing decisions are being made without systematic evidence about what happens to cardiac output, blood pressure, or neuromuscular activity after patients swallow the drops they are prescribed. The absence of controlled dose-ranging data means that both safety counseling and therapeutic optimization remain largely guesswork in this growing area of clinical practice.

Oral cannabis oils are among the most commonly prescribed cannabinoid formulations in clinical practice, yet their acute effects on cardiovascular hemodynamics and respiratory muscle physiology remain poorly characterized under controlled conditions. This protocol describes a planned randomized, double-blind, placebo-controlled crossover trial at the Federal University of Rio Grande do Norte in Brazil, in which healthy adults aged 18 to 50 will receive five interventions on separate days: two doses of full-spectrum CBD+THC oil (12.50 mg and 18.75 mg), two doses of THC-only oil (12.50 mg and 18.75 mg), and an MCT oil placebo. The study uses electrical impedance cardiography to measure cardiac output as the primary endpoint, with surface electromyography of respiratory muscles and near-infrared spectroscopy for tissue oxygenation as secondary measures. The mechanistic rationale centers on CB1 receptor-mediated cardiovascular modulation, though much of the supporting literature derives from inhaled cannabis or preclinical models rather than oral formulations.

No participants have been enrolled and no data have been collected. The final sample size remains undetermined, dependent on a planned five-subject pilot study. This deferred approach to power calculation introduces uncertainty about whether the completed trial will have adequate statistical sensitivity. The protocol does not specify a washout period between the five testing sessions, which is a significant concern given the variable and sometimes prolonged elimination half-life of oral THC. The authors acknowledge that this study is intended to generate foundational dose-response data, and they note that additional trials in clinical populations will be needed before any therapeutic or safety conclusions can be drawn.

A Protocol, Not a Finding: What a New Cannabis Cardiovascular Trial Can and Cannot Tell Us

Medical cannabis prescribers are often making dosing decisions in the dark, particularly when it comes to how oral cannabis oils affect the heart and breathing muscles. A new Brazilian research team has published their plan to finally measure this systematically. But before the cannabis community claims a breakthrough, it is worth reading what the paper actually contains: a design, not a result. The protocol itself is genuinely thoughtful. The within-subject crossover architecture is the right choice for this question because oral cannabis pharmacokinetics vary enormously between individuals. Having each participant serve as their own control across five conditions eliminates that variability as a confounding factor. The multi-system monitoring approach, combining impedance cardiography, surface EMG, and near-infrared spectroscopy in the same protocol, is innovative and could yield a richly integrated physiological picture. I do not often see this level of measurement ambition in cannabis research, and the team deserves credit for it.

That said, the protocol has gaps that could undermine its own ambitions. The most consequential is the absence of a specified washout period between the five intervention days. Oral THC has a variable elimination half-life of roughly 20 to 30 hours, with active metabolites persisting even longer. Running five treatment sessions without clearly defined rest intervals is a bit like running five laps on a track without resting between them and claiming each lap represents a fresh performance: the lingering drug from earlier rounds inevitably contaminates what you measure later. Similarly, deferring the sample size calculation to a five-subject pilot is risky. It is like planning a road trip and deciding how much gas you need only after driving the first five miles. The early data will tell you something, but whether it is representative of the full journey is unknown. And the MCT placebo is not pharmacologically inert; medium-chain triglycerides have documented metabolic and hemodynamic properties, meaning the “control” condition is not a true null.

To a patient, I would say: this study has not started collecting results yet, so we still do not have new evidence about how cannabis oils affect your heart or breathing. To a colleague, I would note that the crossover design is smart, but I would want to see washout periods of at least seven days and plasma cannabinoid monitoring before trusting any dose-response conclusions. To a policymaker, I would emphasize that this kind of systematic cardiovascular safety research is exactly what should precede broad clinical adoption, but the healthy-volunteer restriction means it will not directly answer questions about patients with existing heart or lung disease. The publication of a clinical trial protocol is a commitment to rigor and transparency, not a finding. In cannabis medicine, where commercial interest, regulatory pressure, and patient demand often outpace evidence, distinguishing between “we have a plan to study this” and “we have shown this” is not a pedantic distinction; it is the foundation of evidence-based prescribing.

This protocol occupies an early position in the research arc for oral cannabis cardiovascular pharmacology. It represents a pre-data transparency exercise, the kind of registered, pre-specified methodology that the cannabis clinical research field has historically lacked. If successfully executed, it would join a small body of work examining acute hemodynamic responses to cannabinoids, most of which has focused on inhaled cannabis rather than oral formulations. The crossover design and multi-system monitoring set it apart from earlier observational or single-dose studies, and the Brazilian regulatory framework (ANVISA authorization) adds a layer of institutional oversight that strengthens credibility.

From a pharmacological standpoint, clinicians should note that the two dose levels tested (12.50 mg and 18.75 mg THC) are within typical therapeutic ranges for oral cannabis oils, making the eventual data potentially relevant to real prescribing situations. The use of both full-spectrum CBD+THC and THC-only formulations could provide preliminary data on whether CBD modulates THC’s cardiovascular effects, a question with direct implications for product selection. However, until results are published, no prescribing adjustments are warranted. Clinicians who encounter this protocol in the literature should cite it only as a planned methodology and should continue to counsel patients about the absence of standardized cardiovascular safety data for oral cannabis oils.

This is a published clinical trial protocol, not a completed study. It describes planned methodology, interventions, and outcome measures for a randomized, double-blind, placebo-controlled crossover trial and is registered in the Brazilian Clinical Trials Registry. Protocol publications sit below all empirical study designs in the evidence hierarchy because they contain no data. The single most important inference constraint is that no conclusion about whether cannabis or THC oils affect cardiovascular hemodynamics or respiratory muscle activity can be drawn from this document.

Most existing evidence on cannabis and cardiovascular function comes from studies of inhaled cannabis, which has fundamentally different pharmacokinetics from oral administration. Studies by Abdallah and colleagues on vaporized cannabis in advanced COPD and by Morris and colleagues on inhaled cannabis and pulmonary function have contributed to understanding respiratory effects, but their findings cannot be directly extrapolated to sublingual oil formulations. The few oral cannabis pharmacokinetic studies that exist, such as work with Spectrum Yellow oil, have focused on tolerability and absorption rather than hemodynamic endpoints. This protocol, if completed, would be among the first to provide controlled dose-ranging cardiovascular and neuromuscular data specifically for oral cannabis oils, addressing a gap that the existing literature has identified but not yet filled.

Because no data have been collected, this question applies to design choices rather than analytic decisions. The most consequential design choice is the deferred sample size calculation based on a five-subject pilot. If the pilot overestimates the effect size, the final trial will be underpowered and may fail to detect real hemodynamic changes. Conversely, if the pilot underestimates variability, the study could produce false positive findings. A pre-specified sample size based on published hemodynamic variability data from comparable populations would have been a more defensible approach. Additionally, the absence of plasma cannabinoid monitoring means that dose-response analyses will rely on administered dose rather than verified systemic exposure, a distinction that could meaningfully alter interpretation of any eventual findings.

The most likely overinterpretation is treating this protocol as evidence that cannabis oils affect cardiovascular function. It contains no outcome data and cannot support any claim about hemodynamic effects, respiratory muscle activity, or dose-response relationships. Protocol publications are particularly vulnerable to premature citation in reviews and media coverage, where the existence of a registered trial is conflated with the existence of results. Readers should also avoid interpreting ANVISA regulatory authorization as an endorsement of cannabis safety or efficacy; it reflects permission to conduct research, not a clinical determination. The doses tested (12.50 mg and 18.75 mg) are exploratory, not established safe or effective thresholds.

This publication contributes a well-designed, registered protocol for a five-arm crossover trial that could eventually provide the first systematic dose-ranging data on how oral cannabis and THC oils affect cardiac output and respiratory muscle activity in healthy adults. It does not establish any finding about cannabis cardiovascular effects, and no clinical decisions should change based on this document. Its value lies in transparency and pre-registration, and its scientific contribution will be realized only when results are collected, analyzed, and reported.

Did this study find that cannabis oils affect the heart?

No. This publication is a study plan, not a completed study. No participants have been tested, and no data on cardiovascular effects have been collected or reported. Any claims about cannabis and heart effects cannot be attributed to this paper.

Should I be concerned about taking cannabis oil because of this study?

This protocol does not provide any new safety information. If you are currently taking oral cannabis oil, this publication gives no reason to change your approach. Discuss any cardiovascular concerns with your prescribing physician, who can evaluate your individual risk factors.

When will results from this trial be available?

The protocol was registered in April 2024, and recruitment was reported as ongoing in October 2025. Results will depend on enrollment completion, data collection, and the peer review process. There is no announced timeline for publication of findings.

Are the doses in this study similar to what patients typically take?

The planned doses of 12.50 mg and 18.75 mg of THC fall within ranges commonly encountered in medical cannabis prescribing, though individual prescriptions vary widely. These are exploratory doses chosen for research purposes and should not be interpreted as established recommendations.

Have thoughts on this? Share it: